MSCs Treatment, Clinical Trials and Potential Therapies
Since MSCs are multipotent stem cells that can differentiate into many cell types, the potential clinical indications for MSCs becomes endless. MSCs have been explored in treating heart failure, myocardial infarction (heart attack), osteoarthritis, stroke and spinal cord injury around the world and the results are promising.
MSCs is also immunopriviledged and immunosuppressive with strong anti-inflammatory properties that allow it to be used against autoimmune diseases such as Graft Versus Host Disease (GVHD), Crohn's disease, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
Research on MSCs is expanding exponentially. Researchers around the world, have proven that MSCs not only can differentiate into tissues of mesodermal origin such adipocytes, chondrocytes, osteocytes, cardiomyocytes, but also can trans-differentiate into tissues of ectodermal origin such as neurons and epithelial cells, and endodermal origin such as insulin-producing islet cells and hepatocytes in vitro and in vivo.
In addition, we are one of the few groups that have successfully induced MSCs into mesangial cells and nerve cells apart from heart cells, cartilage cells and skin tissues. We are also actively researching into different sources of MSCs to treat different kind of diseases like kidney disease and diabetes. Other than that, we also continue to explore the possibility of allogenic MSCs treatment, which is MSCs transplantation from one donor to another individual.